IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

# Emerging Nanomedicine Strategies For Targeted Cancer Treatment

Sowjanya Pulipati,* Teja Sri Nagabhairava, Mohammad Shafiya Parveen, Mundlapati Kiran Kumar, Shaik Sharmila, Shaik Khaleshavali, Shaik Noureen, Damarla Dharani, Mohana Vaishnavi Gottumukkala

Department of Pharmaceutics, Vignan Pharmacy College, Vadlamudi, Guntur-522213 Andhra Pradesh, INDIA

**Abstract**

The past decade has witnessed a paradigm shift in oncology with the emergence of nanomedicine as a transformative platform for precision cancer therapy. Conventional treatment modalities—including chemotherapy, radiotherapy, and immunotherapy—are frequently constrained by systemic toxicity, suboptimal tumor accumulation, and therapeutic resistance. Engineered nanoplatforms, spanning lipid-based, polymeric, inorganic, and biomimetic systems, offer unprecedented control over drug biodistribution, pharmacokinetics, and intracellular trafficking. By leveraging physicochemical tunability and multifunctional design, these systems enable spatiotemporally regulated therapeutic delivery through both passive targeting mechanisms, such as the enhanced permeability and retention effect, and active ligand-mediated cellular recognition.

Recent advances have expanded nanomedicine beyond single-agent delivery toward programmable, stimuli-responsive constructs capable of integrating chemotherapy, gene modulation, immunotherapy, and phototherapies within unified platforms. Biomimetic strategies—including membrane cloaking and exosome-inspired carriers—further enhance immune evasion and tumor selectivity. Concurrently, rational control of particle size, surface chemistry, and architecture has improved tumor penetration, minimized off-target sequestration, and enabled synergistic multimodal interventions against heterogeneous and metastatic disease.

Despite these advances, translational hurdles persist, including variable tumor microenvironment responses, complex host–nanoparticle interactions, large-scale manufacturing constraints, and regulatory challenges surrounding safety and long-term biodistribution. The convergence of nanotechnology with systems biology, immune engineering, and artificial intelligence-guided formulation design is poised to accelerate clinical translation.

Collectively, emerging nanomedicine strategies redefine the therapeutic landscape of oncology by enabling programmable, multimodal, and patient-adapted interventions, moving cancer treatment closer toward truly precision-driven care.

**Keywords:** Targeted Nanomedicine, Cancer Drug Delivery, Stimuli-Responsive Nanoparticles, Tumor Microenvironment Targeting, Multimodal Cancer Therapy

## 1. Introduction

Nanomedicine has emerged as a highly promising and innovative strategy to significantly enhance cancer treatment outcomes. One of the most significant challenges faced in oncology is that tumors often evade effective therapy, primarily due to various issues related to drug distribution and cellular uptake. In this context, nanoparticles present an attractive platform for targeted cancer drug delivery, offering a myriad of unique properties that are advantageous for therapeutic purposes. These properties include a substantial surface-to-volume ratio, impressively small size, high capacity for drug loading, and tunable surface chemistry, which can be modified to optimize interactions with specific target organs or cells. Such features not only facilitate improved targeting but also enable precise and effective intracellular release of therapeutic agents, thereby potentially overcoming the obstacles encountered with conventional treatment methods. [1,2]

### 1.1 Global Burden of Cancer

Cancer remains one of the leading causes of morbidity and mortality worldwide. According to International Agency for Research on Cancer (IARC) under the World Health Organization, the 2020 GLOBOCAN report estimated 19.3 million new cancer cases and approximately 10 million deaths globally, with projections suggesting a rise to nearly 28.4 million cases by 2040 due to population aging and lifestyle transitions.

The most commonly diagnosed cancers include:

- Breast cancer
- Lung cancer
- Colorectal cancer
- Prostate cancer

The increasing burden is particularly significant in low- and middle-income countries, where late diagnosis and limited access to advanced therapies worsen outcomes.




**Figure 1: Growing up of Global Cancer Burden**




**Figure 2: Prevalence of major cancer types (Global Distribution)**

### 1.2 Limitations of Conventional Cancer Therapies

Despite advances in surgery, chemotherapy, radiotherapy, and immunotherapy, conventional cancer treatments exhibit major limitations:

#### A. Lack of Target Specificity

Cytotoxic chemotherapeutic agents (e.g., doxorubicin, cisplatin) affect both cancerous and healthy proliferating cells, leading to systemic toxicity.

#### B. Severe Side Effects

Myelosuppression, cardiotoxicity, nephrotoxicity, neurotoxicity, and gastrointestinal complications reduce patient compliance.

#### C. Multidrug Resistance (MDR)

Cancer cells overexpress efflux transporters such as P-glycoprotein, reducing intracellular drug concentration.

#### D. Poor Pharmacokinetics

Many anticancer drugs exhibit:

- Low solubility
- Short half-life
- Rapid systemic clearance
- Non-uniform tumor penetration

Consequently, therapeutic windows remain narrow, and treatment failure is common in advanced-stage cancers.

## 2. Nanoparticle Platforms for Targeted Delivery

### 2.1. Lipid-based Nanoparticles

Lipid-based nanoparticles are promising platforms for targeted cancer therapy due to their ability to encapsulate both hydrophilic and hydrophobic agents, including biomacromolecules. These systems are composed of lipids that self-assemble into nanosized vesicles, offering advantages such as biocompatibility, scalability, and cost-effectiveness[4].

The three primary classes include liposomes, solid lipid nanoparticles (SLNs), and ionizable lipid nanoparticles (ILNs). Liposomes are spherical vesicles with one or more lipid bilayers capable of carrying hydrophilic, amphiphilic, and hydrophobic compounds[5]. SLNs are composed of solid lipids, providing high drug-loading capacity, structural stability, and ease of preparation. ILNs, formulated with ionizable lipids, are particularly effective for nucleic acid delivery, including mRNA, and are increasingly explored for anticancer applications.

**Table 1: Comparison of Lipid-Based Nanoparticles as Delivery Systems in Cancer Therapy**

**Comparison of Lipid-Based Nanoparticles as Delivery Systems in Cancer Therapy**

| Type | Structure and Composition | Encapsulated Agents | Key Advantages | Therapeutic Applications |
|---|---|---|---|---|
|  Liposomes | **Liposomes** Spherical vesicles with one or more lipid bilayers surrounding an aqueous core | • Hydrophilic, amphiphilic, and hydrophobic compounds | • Biocompatibility, enhanced solubility, versatility | • Chemotherapy, gene therapy, theranostics |
|  | **Solid Lipid Nanoparticles (SLNs)** Solid lipid matrix encapsulating lipophilic drugs | • Lipophilic drugs | • High drug-loading capacity, structural stability | • Chemotherapy, photodynamic therapy |
|  | **Ionizable Lipid Nanoparticles (ILNs)** Ionizable lipid shell surrounding nucleic acid cargos (e.g., mRNA) | • mRNA, siRNA, other nucleic acids | • Effective mRNA delivery tunable charge | • Gene therapy, including cancer immunotherapy |

### 2.2. Polymer-based Nanoparticles

Polymer-based nanoparticles are a versatile and extensively studied platform for cancer diagnosis and therapy. Their design depends on appropriate polymer selection, functionalization strategies, and efficient drug-loading techniques. Small-molecule–polymer conjugates can self-assemble into well-defined nanoparticles, while biodegradable polymers allow controlled drug release through dissolution or enzymatic hydrolysis[6]. Compared to lipid systems, polymers offer greater flexibility in chemical structure, hydrophobicity, and functionality, enabling customized designs for specific biomedical applications[7]. These systems can accommodate diverse payloads—including small molecules, proteins, peptides, nucleic acids, and dyes—without compromising stability.

Commonly used polymers include PLA, PLGA, PCL, PEG, PEO, and PVA. PLA and PLGA are widely employed due to their biodegradability, sustained-release capability, and regulatory acceptance. PEG imparts a “stealth” effect that reduces protein adsorption and prolongs circulation time. Advanced architectures such as dendritic polymers and nanogels further enhance drug-loading capacity, structural stability, functionalization potential, and controlled release behavior, making polymeric nanoparticles highly adaptable for targeted cancer therapy.

**Table 2: Common Polymers Used in Nanoparticle-Based Cancer Therapy and Their Functional Roles**

| Polymer | Type | Key Properties | Primary Function in Nanocarriers | Advantages in Cancer Therapy |
|---|---|---|---|---|
| **Polylactic Acid (PLA)** | Biodegradable synthetic polymer | Hydrophobic, degradable via hydrolysis | Drug encapsulation and sustained release | Controlled release of hydrophobic drugs; good biocompatibility |
| **Poly(lactic-co-glycolic acid) (PLGA)** | Biodegradable copolymer | Tunable degradation rate; FDA-approved | Systemic nanocarriers, implants, injectable systems | Sustained release; excellent safety profile; clinical translation potential |
| **Polycaprolactone (PCL)** | Biodegradable synthetic polymer | Slow degradation; hydrophobic | Long-term drug delivery systems | Extended drug release; suitable for implants |
| **Polyethylene Glycol (PEG)** | Hydrophilic synthetic polymer | "Stealth" property; reduces protein adsorption | Surface modification (PEGylation) | Prolonged circulation time; reduced immunogenicity; enhanced tumor accumulation |
| **Polyethylene Oxide (PEO)** | Hydrophilic polymer | Similar to PEG; water-soluble | Stabilizer and surface modifier | Improved nanoparticle stability; reduced aggregation |
| **Polyvinyl Alcohol (PVA)** | Synthetic polymer | Emulsifying and stabilizing agent | Nanoparticle stabilization during preparation | Enhanced structural stability; improved particle uniformity |
| **Dendritic Polymers (e.g., PAMAM dendrimers)** | Hyperbranched macromolecules | Highly defined structure; multiple functional groups | Multi-drug conjugation and gene delivery | High drug-loading capacity; precise functionalization |
| **Nanogels (Cross-linked polymers)** | Cross-linked hydrogel network | Swelling/de-swelling capability | Encapsulation of hydrophilic drugs and biomolecules | High payload retention; stimuli-responsive controlled release |

### 2.3. Inorganic Nanoparticles

Cancer therapy increasingly employs inorganic nanoparticles as delivery systems for drugs, genes, and biotherapeutics. These nanocarriers include materials such as carbon, silica, iron oxide, gold, and other metals, used for tumor diagnosis and therapy either separately or in integrated theranostic approaches. Although polymeric and lipid-based systems account for nearly 90% of commercially available

formulations, inorganic nanocarriers offer advantages such as extended blood circulation and multifunctionality.

Common inorganic platforms include nanoparticles (1–100 nm), nanocapsules, and nanoshells. Nanoparticles can function both as therapeutic agents and carriers for small molecules, proteins, or genes, and may also template other systems such as liposomes or micelles. Nanocapsules possess an impermeable coating encapsulating therapeutic agents, whereas nanoshells consist of a core–shell structure with tunable size and porosity [8].

Safety concerns remain under investigation. Surface engineering with polymer coatings such as polyethylene glycol (PEG) or polyvinyl alcohol (PVA) can reduce toxicity and improve biocompatibility. However, safety profiles vary depending on the metal composition, surface characteristics, and core structure, all of which significantly influence biodistribution and in vivo fate [9].

### 2.4. Biomimetic and Hybrid Nanostructures

Biomimetic and hybrid nanostructures represent an emerging strategy in nanomedicine that integrates biological components with engineered nanoparticles for disease-targeted therapy. By utilizing biological substrates—such as cancer cell membranes, stem cells, red blood cell membranes, viral proteins, and exosomes—these systems can evade immune recognition and enhance receptor-specific targeting.

Nanoparticles are often coated with lipid layers or biological membranes to achieve “stealth” properties, reducing rapid clearance by the reticuloendothelial system. Additional functionalization with antibodies, ligands, or endogenous receptor-binding molecules further improves tissue specificity. Hybrid systems combining passive targeting through the enhanced permeability and retention (EPR) effect with active receptor-mediated endocytosis, sometimes integrated with stimuli-responsive elements, enable precise and efficient drug delivery within tumor tissues.

## 3. Targeting Strategies and Mechanisms

Nanoparticles accumulate in tumors primarily through the enhanced permeability and retention (EPR) effect, enabling passive targeting without the need for specific ligands. Although the EPR effect occurs in both animal models and humans, tumor accumulation in humans is typically lower. Despite the clinical use of polymeric and lipid-based nanocarriers, effective systemic tumor targeting remains limited, highlighting the need for improved delivery strategies[10].

Currently approved nanomedicines are mainly liposomal or albumin-based formulations that rely on passive targeting and demonstrate improved efficacy and reduced toxicity compared with free drugs. To enhance specificity, active targeting approaches utilize ligands such as folic acid, hyaluronic acid, antibodies, peptides (e.g., RGD, iRGD), and aptamers. However, additional targeting moieties may alter biodistribution, prolong circulation, and promote unintended accumulation in healthy tissues. Moreover, macrophage uptake within tumors can significantly reduce effective drug delivery[11].

Emerging strategies combine passive and active targeting, including surface-engineered systems and multifunctional carriers. Given the diversity of nanoparticle design parameters—such as surface chemistry, hydrophobicity, and ligand density—systematic research is essential to better understand how these properties influence biodistribution, tumor penetration, and therapeutic efficacy.

### 3.1. Passive Targeting via EPR Effect

Passive targeting through the enhanced permeability and retention (EPR) effect distinguishes nanoparticles from small-molecule drugs and macromolecules, including proteins and antibodies, facilitating drug accumulation in solid tumors. Solid tumors possess aberrant blood supply, rapid vascularization, and fenestrated endothelium. In normal tissues, the loss of microvascular integrity and fenestrated endothelium is followed by lymphatic drainage, while EPR in tumors allows nanoparticles of 5 to 200 nm to enter tumor tissue without significant clearance by lymphatic vessels [12]. However, the presence of an intact lymphatic network and survival of primary high-microvascular-density tumors limit EPR-mediated targeting to certain tumor types.

### 3.2. Active Targeting through Ligand-Receptor Interactions

Active targeting enhances nanoparticle specificity through ligand–receptor interactions that promote receptor-mediated endocytosis or membrane fusion. Nanoparticles designed to mimic natural biomolecules—such as lipids, polysaccharides, proteins, and nucleotides—facilitate improved cellular recognition while maintaining structural flexibility and stability. Chemical modification of lipid and polymer nanocarriers enhances drug stability, bioavailability, and circulation time, whereas biomimetic approaches (e.g., cell membrane cloaking) enable immune evasion and targeted cellular uptake[13].

Lipid bilayer–coated nanoparticles resemble native cellular membranes, improving biological barrier penetration and receptor-specific binding. Core–shell systems incorporating biological components such as cell membranes or viral proteins further enhance selectivity and prolong circulation. Ligand-functionalized systems—including folate-linked prodrugs and other receptor-targeting constructs—enable preferential tumor accumulation, while pH-responsive polymeric systems exploit the acidic tumor microenvironment to improve drug release[10]. Amphiphilic polymer–drug conjugates further enhance deep tumor penetration, supporting more efficient therapeutic delivery.

### 3.3. Stimuli-Responsive and Environmentally Activated Systems

Stimuli-responsive nanosystems are engineered to modify their physicochemical properties in response to internal (pH, redox potential, enzymes) or external (light, temperature, magnetic fields) triggers [14]. These systems enable site-specific and on-demand drug release, thereby improving therapeutic efficacy while minimizing systemic toxicity. By shielding drugs during circulation and activating them only at the target site, they enhance solubility, prolong blood circulation, and reduce off-target effects. Some platforms also allow real-time monitoring and external modulation of therapeutic activity.

Stimuli-responsive polymeric nanocarriers are often formed through self-assembly of amphiphilic diblock copolymers into core–shell structures. The hydrophobic core encapsulates drugs, preventing premature release, while the hydrophilic shell enhances stability in physiological fluids. pH-responsive systems can be developed using amine-containing polymers such as PEG or poly(2-aminoethyl methacrylate) (PAEMA), combined with pH-sensitive polymers, enabling selective drug release in the acidic tumor microenvironment[15].




**Figure 3: Stimuli-Responsive Nanocarriers in Cancer Therapy**

## 4. Therapeutic Modalities in Nanomedicine

Nanoparticles offer advanced therapeutic strategies in cancer treatment due to their high surface-to-volume ratio, small size, drug encapsulation capacity, and tunable surface chemistry [2]. These features enable targeted delivery, improved biodistribution, enhanced intracellular uptake, and sustained drug release, thereby overcoming limitations of free drugs such as systemic toxicity and rapid clearance. Multifunctional nanocarriers capable of co-delivering multiple agents provide a promising approach for managing complex and resistant tumors.

Targeted lipid-, polymer-, inorganic-, and biomimetic-based nanoplatforms are actively explored for their safety, adaptability, and compatibility with existing treatment modalities. These systems address key tumor-related challenges including selective accumulation, deep tissue penetration, controlled release, and reduced off-target effects [16].

Major therapeutic modalities include chemotherapy enhancement, gene and siRNA delivery, photothermal therapy (PTT), photodynamic therapy (PDT), and immunomodulation**,** often combined within single nanoplatforms to achieve synergistic anticancer effects [17].




**Figure 4: Therapeutic modalities in Nanomedicine**

### 4.1. Chemotherapy-Loaded Nanocarriers

Nanotechnology provides an opportunity to investigate new strategies for cancer treatment by employing nanocarrier systems capable of controlling the delivery of antitumor drugs to cancer cells [18]. Current strategies based on the enhanced permeability and retention (EPR) effect have shown promising results, but drug penetration and accumulation remain important challenges that need to be addressed [19]. A large number of studies have demonstrated that polymeric nanoparticles, liposomes, dendrimers, carbon-based nanoparticles, micelles, nanocrystals, inorganic nanoparticles, silica and metal nanoparticles loaded with a single or a cocktail of antitumor drugs can be used to treat a wide variety of cancers in vitro and *in-vivo* [20]. These nanocarriers are capable of improving drug solubility and bioavailability, controlling spatiotemporal drug release, and decreasing systemic and off-target toxicity.

### 4.2. Gene and siRNA Delivery Systems

Nucleotide-based systems, particularly small interfering RNA (siRNA) and messenger RNA (mRNA), offer an attractive means of treating cancer due to their ability to selectively silence the expression of disease-related genes. The unique structure of siRNA allows the design of specific molecules to silence virtually any target gene linked to disease initiation or progression, and the prospective ability to reduce the expression of drug efflux pumps might prove broadly useful for reversing acquired drug resistance [21]. Four siRNA drugs have been approved since the first in 2018, yet none are for tumor indications [22]. As designing any sequence of nucleotide within a target construct is a straightforward process, mRNA vaccines and therapeutics have swiftly gained traction. Quality control and production of mRNA remain far from trivial to achieve consistently.

### 4.3. Photothermal and Photodynamic Therapies

Photothermal and photodynamic therapies are innovative cancer treatments using light-absorbing and light-emitting nanomaterials to induce hyperthermia or generate reactive oxygen species upon near-infrared (NIR) illumination. Gold, iron oxide, and copper sulfide nanoparticles; graphitic carbon nanomaterials; porphyrin-based compounds; and similar agents can serve as photothermal agents or photosensitizers [23]. These nanosystems can be conjugated to targeting moieties (e.g., antibody fragments, peptides) or loaded with chemotherapeutics to gain a targeted-delivery capability, enabling simultaneous activation of both photothermal and photodynamic therapeutic pathways. Such combinatorial treatment approaches have a high potential for synergistic action, permitting lower doses of both agents while enhancing overall efficacy [24].

### 4.4. Immunomodulatory Nanomedicine

In recent decades, cancer treatment has focused mainly on cytotoxic chemotherapy and radiotherapy, directed against tumor cells to control proliferation and spread. In addition to cytotoxic agents, a variety of approaches have emerged to enhance the stimulation of the patient's immune system to eliminate tumor cells. Immunotherapeutic agents are often highly effective in robustly activating the immune system against either fixed or newly presented tumor antigens. However, they may sometimes require co-administration of agents to increase the abundance of antigen-presenting cells at the tumor site, directly enhance immune-effector cell function, or produce additional danger signals to enhance therapeutic outcome [25]. Immunotherapy can also remain largely ineffective if the tumor and other tissues express upregulated immuno-suppressive factors. To address limitations in the reach and duration of action of immunotherapy, the additional application of nanomedicine-based carriers has been proposed to deliver chemotherapeutics, adjuvants, and biologics such as plasmid DNA and small RNA, including miRNA, siRNA, and shRNA, into specific cell sub-populations of the immune system at regulated time intervals. These sub-populations include dendritic cells, T cells, natural-killer (NK) cells, tumor-associated macrophages (TAMs), and monocytes [26]. Immuno-suppressed conditions in the tumor micro-environment induced by various oncogenic factors, such as cytokines and growth factors, can be partly restored or amplified by targeting TAMs and related myeloid cells with specific formulations of RNA nanomedicine [27]. Improved targeting predominately to myeloid cells instead of lymphocytes can also be achieved via appropriately selected lipid compositions and extra-functionalization of surface ligands.

## 5. Overcoming Barriers to Effective Delivery

Efficient delivery of cancer therapeutics is constrained by multiple barriers, including tumor penetration, interstitial pressure, hypoxia, and stromal composition [28]. Precise yet broad combinations of active targeting and stimuli-responsive mechanisms, coupled with sophisticated platform design, can help to

navigate such impediments [29]. Tumor neoangiogenesis produces poorly organized, "leaky" vasculature with abnormal structure, morphology, and distribution, contributing to a relative high interstitial fluid pressure (IFP) that curtails nanoparticle transport; lymphatic vessels are practically absent—another contributing factor—resulting in prolonged systemic circulation and mediating common sequestration at organs such as the liver.

Characterisation of tumors and the tumor microenvironment (TME) enables access to strategies for overcoming barriers associated with conventional chemotherapy; some recent developments also aim at co-delivering anticancer agents to tumours and adjacent organs [30]. Advanced payload design or multifunctional nanomaterials that couple the delivery of therapeutics to specific sites while simultaneously eliciting treatment have the potential to alleviate or even entirely overcome these transport barriers.

Location of tumor, type of drug and timing of therapy commenced greatly affect the performance of tumor-targeted therapeutics; context-sensitive concept of "targeting" provides guidance for building high-performance carriers. Metastatic spread, often taking place long before surgical excision of the primary tumour, poses another key challenge for patient survival; accordingly, tampering the CAR-T (T-cells expressing Chimeric Antigen Receptor) therapy with small-molecule drugs like selinexor (an XPO1-inhibitor) may be a promising combinatorial regimen. Emerging combinatorial therapeutic approaches therefore propose to alleviate hidden metastasis and prevent rapid rebound of untargeted cells.

Finally, overall biodistribution, clearance pathway, and safety assessment are modulable through particle design and material selection. Certain chronic inflammation-associated biophysical changes present in most cancer types also suggest new possibilities for developing selective delivery approaches.

### 5.1. Tumor Microenvironment Challenges

Efficient cancer drug delivery is limited by multiple biological barriers, including poor tumor penetration, elevated interstitial fluid pressure (IFP), hypoxia, dense stromal structure, and abnormal vasculature. Tumor neoangiogenesis produces disorganized and leaky blood vessels with minimal lymphatic drainage, restricting nanoparticle transport while promoting sequestration in organs such as the liver [31].

Combining active targeting with stimuli-responsive systems and optimized nanocarrier design can improve navigation across these barriers. Detailed characterization of the tumor microenvironment (TME) enables development of multifunctional nanoplatforms capable of site-specific delivery and controlled release, thereby enhancing therapeutic efficacy and reducing off-target effects. Co-delivery strategies targeting both tumors and surrounding tissues are also being explored [32].

Therapeutic performance depends on tumor location, drug type, and treatment timing, highlighting the need for context-specific targeting approaches. Addressing metastatic spread remains critical; combinatorial regimens, including immunotherapies such as CAR-T cells integrated with small-molecule agents, are emerging strategies to prevent relapse and eliminate residual disease.

Ultimately, biodistribution, clearance, and safety can be tailored through rational particle design and material selection, offering opportunities to overcome physiological transport barriers in cancer therapy.

### 5.2. Biodistribution, Clearance, and Safety Considerations

Nanoparticles are attractive platforms for cancer-targeted delivery due to their versatility in drug encapsulation and surface modification. Targeting occurs through passive mechanisms, primarily the enhanced permeability and retention (EPR) effect, or active ligand–receptor interactions requiring precise surface engineering. However, growing evidence shows that even well-designed nanoparticles frequently accumulate in off-target organs, particularly the liver and spleen, leading to prolonged retention, reduced therapeutic efficiency, and potential toxicity [10,33].

Understanding how particle size, surface chemistry, charge, and material composition influence biodistribution, metabolism, and clearance is therefore essential. Tumor accumulation does not always correlate with therapeutic success, and some tumor types display minimal targeted uptake. Additionally,

nanoparticles can alter the pharmacokinetics of associated drug payloads, and their long-term degradation and elimination pathways may differ from expected safety profiles.

Design strategies aimed at minimizing unintended distribution further increase system complexity, while comprehensive data on how specific targeting approaches affect clearance pathways remain limited. Consequently, optimizing biodistribution and safety continues to be a critical challenge in the clinical translation of targeted nanomedicines.




**Figure 5: Schematic representation of biodistribution, clearance and safety of targeted nanoparticles**

### 5.3. Scalability and Manufacturing Standards

Nanoparticle-based drug delivery systems enable targeted anti-cancer therapeutics with improved circulation half-life, bioavailability, distribution, pharmacokinetics, and safety profiles. A viable nanocarrier should be biodegradable, biocompatible, capable of effective homing to the target site, exhibit optimal biophysicochemical properties for superior drug loading, circulation, and sustained release, and remain cost-effective for scale-up[1]. Simultaneous delivery of multiple modalities poses yet another challenge, as does compliance with manufacturing, regulation, and approval processes that differ substantially from conventional formulations. Formal studies have outlined a range of options for precise characterization at various stages and stress the need to establish quality-control guidelines and pass U.S. Food and Drug Administration trials [2]. Despite these hurdles, nanomedicine holds significant potential for innovative therapeutic solutions.

## 6. Preclinical Evaluation and Clinical Translation

Preclinical studies are essential for validating the safety and efficacy of targeted nanomedicines prior to human trials. In vitro models provide cost-effective, high-throughput evaluation of cellular interactions, toxicity, and mechanistic pathways, but they cannot predict organ-specific biodistribution, immune responses, or long-term fate. These aspects require in vivo models, which better capture systemic behavior but involve greater complexity and cost. Although larger animal models offer closer physiological similarity to humans, they may not fully replicate human tumor biology. Therefore, nanomedicine studies must be carefully designed to generate clinically relevant data.

Clinical translation remains challenging due to the need for scalable manufacturing, rigorous analytical validation, and coordinated clinical infrastructure. Key barriers include limited predictive dosing strategies and variability in tumor biology and host responses [2]. Establishing optimal dosing regimens and achieving reproducible, cost-effective large-scale synthesis are critical steps toward successful clinical evaluation and commercialization of nanomedicines.

### 6.1. *In-Vitro* and *In-Vivo* Model Systems

Modeling is an integral part of the discovery and development of therapeutic agents as it enables prediction of animal and human outcomes from in vitro and/or animal models. Small animal models, including mice and rats, are relevant because of their genetic, biological and immunological similarity to humans and their rapid disease progression, genetic manipulation capabilities, and overall reduced upkeep costs. Rodent models must be complemented with larger animal models possessing more relevant body burdens of organ-specific lipidity, and exert functions compared to rodents including internalizing protein expression for metabolizing and modifying chemicals, and infections and tissues which are similar to humans. Non-human primate models have a central place for preclinical evaluation because of the genetic and physiological proximity with humans. For certain nanomedicine applications, such as infections, tumor imaging, and cardiomyopathies, modelling can be completely avoided using an appropriate strategy.

In addition to selecting the appropriate animal model, a basic requirement for predicting in vivo behavior is the selection of the right set of experimental conditions. For instance, monitoring tissue distribution using commercially available nanoparticles is not necessarily representative of experimental agents. The introduction of radioactive isotopes or near infrared dye in the nanostructure enables tracking during in vivo evaluation, which represents the delivery transiting directly from injection site to organs, thus ignoring the actual delivery. Observing the biodistribution by loading the drug post-synthesis on the nanocarrier is usually non-specific as the lipid bilayers of liposomes would be recognized by the liver. Therefore, to remain close to reality, the drug must be encapsulated prior to polymeric or liposomal formation. Apart from biodistribution, the pharmacodynamics are often scrutinized using models mimicking a subset of diseases such as cancer or neurodegeneration.

### 6.2. Regulatory and Ethical Considerations

Successful translation of nanomedicines from bench to bedside requires a clearly defined regulatory pathway and early integration of safety evaluation. Regulatory agencies increasingly mandate comprehensive safety data before initiating clinical trials, particularly for oncology therapies [34]. This has strengthened the adoption of safe-by-design approaches, where nanoparticles are engineered to optimize targeting efficiency while minimizing immune activation and unintended toxicity.

Robust characterization and traceability of nanomedicine formulations throughout development are critical. All materials and equipment in contact with formulations must be assessed for potential contamination or leachables, as improper sterilization or processing can compromise nanoparticle integrity and performance.

Ethical considerations are equally important during preclinical development. Appropriate selection of animal models, including species, strain, age, and study design, must be justified to ensure scientific validity while minimizing animal suffering. Analytical methods should be validated according to regulatory standards before experimentation to ensure reliability and avoid unnecessary exposure of test subjects.

## 7. Future Directions and Emerging Trends

Nanomedicine is advancing cancer therapy by enabling targeted drug delivery and multimodal treatment strategies [1]. Conventional treatments—surgery, chemotherapy, radiotherapy, and immunotherapy—often lack spatial and temporal precision, resulting in systemic toxicity, prolonged treatment duration, and multidrug resistance [2]. Targeted nanocarriers improve therapeutic concentration at tumor sites while minimizing off-target effects, particularly when combined with stimuli-responsive release mechanisms triggered by tumor-specific or external signals.

Nanoparticles derived from lipid, polymeric, inorganic, and biomimetic materials form the basis of modern targeted therapies. Therapeutic agents—such as cytotoxic drugs, genes, siRNA, proteins, and

photothermal agents—can be encapsulated, conjugated, or surface-adsorbed depending on material properties that influence biocompatibility, hydrophilicity, and delivery performance [35-37].

Despite significant progress, challenges remain, including incomplete elimination of nanocarrier residues, limited effectiveness across diverse tumor types, unintended organ accumulation, and systemic toxicity. Addressing these limitations through smarter design, precision targeting, and improved biodegradability will shape the next generation of clinically translatable nanomedicines [38,39].

## 8. Conclusion

Nanomedicine is emerging as a powerful platform to address pressing challenges in cancer management. Engineered nanoparticles with well-defined surfaces and compositions present opportunities for improving the safety and anti-tumor efficacy of existing cancer therapies [1]. In preclinical and early clinical settings, various nanoparticle systems have demonstrated greater accumulation and penetration into tumors and controlled in vivo release of anti-cancer agents than conventional systems. At the same time, a comprehensive understanding of relevant physiological factors, materials chemistry, and system engineering requirements is necessary to inform the design of nanoplatforms that address specific clinical needs and enable successful product development [34].

## 9. References:

1. Xu X, Ho W, Zhang X, Bertrand N et al. Cancer Nanomedicine: From Targeted Delivery to Combination Therapy. 2015. ncbi.nlm.nih.gov

2. Xu X, Ho W, Zhang X, Bertrand N et al. Cancer Nanomedicine: From Targeted Delivery to Combination Therapy. 2016. [PDF]

3. Fernandes S, Cassani M, Cavalieri F, Forte G et al. Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid-Based Nanoparticles. 2023. ncbi.nlm.nih.gov

4. Camila Marques A, C. Costa P, Velho S, Helena Amaral M. Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy. 2023. ncbi.nlm.nih.gov

5. Sheoran S, Arora S, Samsonraj R, Govindaiah P et al. Lipid-based nanoparticles for treatment of cancer(). 2022. ncbi.nlm.nih.gov

6. Xia W, Tao Z, Zhu B, Zhang W et al. Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy. 2021. ncbi.nlm.nih.gov

7. Gad A, Kydd J, Piel B, Rai P. Targeting Cancer using Polymeric Nanoparticle mediated Combination Chemotherapy. 2016. ncbi.nlm.nih.gov

8. Wang F, Li C, Cheng J, Yuan Z. Recent Advances on Inorganic Nanoparticle-Based Cancer Therapeutic Agents. 2016. ncbi.nlm.nih.gov

9. Naz S, Shamoon M, Wang R, Zhang L et al. Advances in Therapeutic Implications of Inorganic Drug Delivery Nano-Platforms for Cancer. 2019. ncbi.nlm.nih.gov

10. S. Drozdov A, I. Nikitin P, M. Rozenberg J. Systematic Review of Cancer Targeting by Nanoparticles Revealed a Global Association between Accumulation in Tumors and Spleen. 2021. ncbi.nlm.nih.gov

11. Li J, Wang Q, Xia G, Adilijiang N et al. Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy. 2023. ncbi.nlm.nih.gov

12. Dhaliwal A, Zheng G. Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery. 2019. ncbi.nlm.nih.gov

13. J. Yoon D, T. Liu C, S. Quinlan D, M. Nafisi P et al. Intracellular Trafficking Considerations in the Development of Natural Ligand-Drug Molecular Conjugates for Cancer. 2011. ncbi.nlm.nih.gov

14. Li L, Wang J, Kong H, Zeng Y et al. Functional biomimetic nanoparticles for drug delivery and theranostic applications in cancer treatment. 2018. ncbi.nlm.nih.gov

15. Kang B, Kukreja A, Song D, Huh YM et al. Strategies for using nanoprobes to perceive and treat cancer activity: a review. 2017. ncbi.nlm.nih.gov

16. Chakraborty K, Tripathi A, Mishra S, Mallick AM et al. Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment. 2022. ncbi.nlm.nih.gov

17. Mfouo Tynga I, Abrahamse H. Nano-mediated photodynamic therapy for Cancer : enhancement of cancer specificity and therapeutic effects. 2018. [PDF]

18. Zhang J, Tang H, Liu Z, Chen B. Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug delivery system in targeted chemotherapy. 2017. ncbi.nlm.nih.gov

19. Xiang J, Zhao R, Wang B, Sun X et al. Advanced Nano-Carriers for Anti-Tumor Drug Loading. 2021. ncbi.nlm.nih.gov

20. Shukla A, Maiti P. Nanomedicine and versatile therapies for cancer treatment. 2022. ncbi.nlm.nih.gov

21. Huang J, Xiao K. Nanoparticles-Based Strategies to Improve the Delivery of Therapeutic Small Interfering RNA in Precision Oncology. 2022. ncbi.nlm.nih.gov

22. Mahmoodi Chalbatani G, Dana H, Gharagouzloo E, Grijalvo S et al. Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach. 2019. ncbi.nlm.nih.gov

23. A Hussein E, M Zagho M, K Nasrallah G, A Elzatahry A. Recent advances in functional nanostructures as cancer photothermal therapy. 2018. ncbi.nlm.nih.gov

24. Estelrich J, Antònia Busquets M. Iron Oxide Nanoparticles in Photothermal Therapy. 2018. ncbi.nlm.nih.gov

25. Yu M, Yang W, Yue W, Chen Y. Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation. 2022. ncbi.nlm.nih.gov

26. Zhu J, Fan J, Xia Y, Wang H et al. Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy. 2023. ncbi.nlm.nih.gov

27. Volovat SR, Lupascu Ursulescu C, Gheorghe Moisii L, Volovat C et al. The Landscape of Nanovectors for Modulation in Cancer Immunotherapy. 2022. ncbi.nlm.nih.gov

28. Rosenblum D, Joshi N, Tao W, M. Karp J et al. Progress and challenges towards targeted delivery of cancer therapeutics. 2018. ncbi.nlm.nih.gov

29. Soni A, Prasad Bhandari M, Kant Tripathi G, Bundela P et al. Nano-biotechnology in tumour and cancerous disease: A perspective review. 2023. ncbi.nlm.nih.gov

30. Morales-Cruz M, Delgado Y, Castillo B, M Figueroa C et al. Smart Targeting To Improve Cancer Therapeutics. 2019. ncbi.nlm.nih.gov

31. Avgoustakis K, Angelopoulou A. Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments. 2024. ncbi.nlm.nih.gov

32. Fernandes C, Suares D, C Yergeri M. Tumor Microenvironment Targeted Nanotherapy. 2018. [PDF]

33. M. Dawidczyk C, M. Russell L, C. Searson P. Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. 2014. ncbi.nlm.nih.gov

34. Rodríguez F, Caruana P, De la Fuente N, Español P et al. Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges. 2022. ncbi.nlm.nih.gov

35. Xu JJ, Zhang WC, Guo YW, Chen XY et al. Metal nanoparticles as a promising technology in targeted cancer treatment. Drug Delivery. 2022. tandfonline.com

36. Das KP. Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges. Frontiers in medical technology. 2023. frontiersin.org

37. Emeihe EV, Nwankwo EI, Ajegbile MD, Olaboye JA, Maha CC. Revolutionizing drug delivery systems: Nanotechnology-based approaches for targeted therapy. International Journal of Life Science Research Archive. 2024 Aug;7(1):40-58. researchgate.net

38. Munir MU. Nanomedicine penetration to tumor: challenges, and advanced strategies to tackle this issue. Cancers. 2022. mdpi.com

39. Harishchandra VB. Nanoparticle Applications in Drug Delivery: Progression, Hurdles, and Prospects. researchgate.net. . researchgate.net